Consolidated Statements of Stockholders (Deficit) Equity - USD ($) $ in Thousands	Common Stock Series B Preferred Stock	Common Stock	Series B Preferred Series B Preferred Stock	Series B Preferred	Additional Paid-in Capital Series B Preferred Stock	Additional Paid-in Capital	Accumulated Deficit Series B Preferred Stock	Accumulated Deficit	Accumulated Other Comprehensive income	Treasury Stock	Non-Controlling Interest	Total
Balance at Dec. 31, 2020		$ 3		$ 2,477		$ 240,847		$ (248,094)			$ (2,773)	$ (7,540)
Balance (in shares) at Dec. 31, 2020		2,925,270		3,973
Stock-based compensation						416						416
Stock issued under "at-the-market" offering		$ 8				65,952						65,960
Stock issued under "at-the-market" offering (in shares)		7,868,532
Warrants Exercised		$ 1				8,041						$ 8,042
Warrants Exercised (In shares)		1,165,575										0
Series A Preferred Stock Dividends								(24)				$ (24)
Effect of Series A Preferred Stock price adjustment						7,402		(7,402)
Conversion of Series A Preferred Stock to Common		$ 1				12,821						12,822
Conversion of Series A Preferred Stock to Common (in shares)		899,677
Conversion of Series B Preferred Stock to Common			$ (2,477)		$ 3,974		$ (1,497)
Conversion of Series B Preferred Stock to Common (in shares)	345,478		(3,973)
Net loss												(14,267)
Net loss								(14,267)			(1)	(14,268)
Non-controlling interest												1
Reversal of noncontrolling interest due to return of Syn Biomics shares						(2,774)					$ 2,774
Balance (in shares) at Dec. 31, 2021		13,204,531
Balance at Dec. 31, 2021		$ 13				336,679		(271,284)				65,408
Stock-based compensation						112						112
Issuance of Common Stock for VCN Acquisition		$ 3				6,596						6,599
Issuance of Common Stock for VCN Acquisition (in shares)		2,639,530
Translation gains (losses)									$ 181			181
Net loss								(4,273)				(4,273)
Balance (in shares) at Mar. 31, 2022		15,844,061
Balance at Mar. 31, 2022		$ 16				343,387		(275,557)	181			68,027
Balance at Dec. 31, 2021		$ 13				336,679		(271,284)				65,408
Balance (in shares) at Dec. 31, 2021		13,204,531
Net loss												(8,750)
Net loss												(8,750)
Balance (in shares) at Jun. 30, 2022		15,844,061
Balance at Jun. 30, 2022		$ 16				343,500		(280,034)	(1,261)			62,221
Balance at Dec. 31, 2021		$ 13				336,679		(271,284)				65,408
Balance (in shares) at Dec. 31, 2021		13,204,531
Net loss												(13,240)
Net loss												(13,240)
Balance (in shares) at Sep. 30, 2022		15,844,061
Balance at Sep. 30, 2022		$ 16				343,621		(284,524)	(2,725)			56,388
Balance at Dec. 31, 2021		$ 13				336,679		(271,284)				65,408
Balance (in shares) at Dec. 31, 2021		13,204,531
Stock-based compensation						475						475
Issuance of Common Stock for VCN Acquisition		$ 3				6,596						6,599
Issuance of Common Stock for VCN Acquisition (in shares)		2,639,530
Translation gains (losses)									(679)			(679)
Net loss												(19,685)
Net loss								(19,685)				(19,685)
Non-controlling interest												0
Balance (in shares) at Dec. 31, 2022		15,844,061
Balance at Dec. 31, 2022		$ 16				343,750		(290,969)	(679)	$ (288)		51,830
Balance at Mar. 31, 2022		$ 16				343,387		(275,557)	181			68,027
Balance (in shares) at Mar. 31, 2022		15,844,061
Stock-based compensation						113						113
Translation gains (losses)									(1,442)			(1,442)
Net loss								(4,477)				(4,477)
Net loss												(4,477)
Balance (in shares) at Jun. 30, 2022		15,844,061
Balance at Jun. 30, 2022		$ 16				343,500		(280,034)	(1,261)			62,221
Stock-based compensation						(121)						(121)
Translation gains (losses)									(1,464)			(1,464)
Net loss								(4,490)				(4,490)
Net loss												(4,490)
Balance (in shares) at Sep. 30, 2022		15,844,061
Balance at Sep. 30, 2022		$ 16				$ 343,621		$ (284,524)	$ (2,725)			$ 56,388
Treasury Stock (In shares)												720,000
Treasury Stock										$ (288)		$ (288)